23-MULTI-60-BT-PMC (BCA101X1101): First-in-Human, Phase 1/1b, Open-label, Multicenter Study of Bifunctional EGFR/TGFbeta; Fusion Protein BCA101 Monotherapy and in Combination Therapy in Patients with EGFR-Driven Advanced Solid Tumors

Grants and Contracts Details

StatusActive
Effective start/end date10/3/23 → 10/3/25

Funding

  • Bicara Therapeutics Incorporated: $40,080.00